Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 ('SEBI (LODR) Regulations, 2015') Eris Lifesciences Ltd - 540596 - Board Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended 30 June 2023
Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 ,inter alia, to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30 June 2023 Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING. Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
ALLOTMENT OF EQUITY SHARES PURSUANT TO ESOP-2017 SCHEME & ESOP-2021 SCHEME. Individual sells 2 per cent stake in Eris Lifesciences for Rs 188 crore
Rakesh Shah disposed of 27 lakh shares, amounting to a 1.98 per cent stake, at an average price of Rs 697 apiece Eris Lifesciences Ltd - 540596 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June 2023. Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING Eris Lifesciences Ltd - 540596 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amit Indubhushan Bakshi Eris Lifesciences Ltd - 540596 - TRANSFER OF DERMATOLOGY BRANDS FROM ERIS OAKNET HEALTHCARE PVT. LTD TO THE COMPANY.
We would like to inform that Eris Oaknet Healthcare Private Limited, a wholly owned subsidiary, has transferred to the Company all the dermatology trademarks that had been previously acquired from Glenmark Pharmaceuticals Limited and reported vide our disclosure dated 17 January 2023. Eris Lifesciences Ltd - 540596 - Closure of Trading Window
Intimation of closure of trading window.